Northern Trust Corp grew its stake in shares of Viewray Inc (NASDAQ:VRAY) by 71.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 162,504 shares of the company’s stock after purchasing an additional 67,655 shares during the period. Northern Trust Corp owned approximately 0.28% of Viewray worth $1,051,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Nationwide Fund Advisors lifted its position in Viewray by 843.2% during the 2nd quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock valued at $107,000 after acquiring an additional 14,789 shares during the period. TIAA CREF Investment Management LLC raised its holdings in Viewray by 2,447.3% in the second quarter. TIAA CREF Investment Management LLC now owns 286,365 shares of the company’s stock worth $1,853,000 after buying an additional 275,123 shares during the last quarter. Teachers Advisors LLC raised its holdings in Viewray by 668.8% in the second quarter. Teachers Advisors LLC now owns 53,782 shares of the company’s stock worth $348,000 after buying an additional 46,786 shares during the last quarter. White Pine Capital LLC purchased a new position in Viewray in the second quarter worth about $173,000. Finally, Alliancebernstein L.P. bought a new stake in shares of Viewray in the second quarter worth approximately $248,000. 50.08% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Viewray Inc (NASDAQ VRAY) traded down $0.19 during trading on Friday, hitting $9.26. 447,939 shares of the company traded hands, compared to its average volume of 599,513. The stock has a market cap of $638.29, a price-to-earnings ratio of -8.19 and a beta of 0.11. The company has a quick ratio of 1.20, a current ratio of 1.59 and a debt-to-equity ratio of -1.67. Viewray Inc has a 52-week low of $3.01 and a 52-week high of $10.39.
A number of research firms have weighed in on VRAY. BidaskClub upgraded shares of Viewray from a “hold” rating to a “buy” rating in a research report on Friday, December 22nd. ValuEngine downgraded shares of Viewray from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Northland Securities reaffirmed a “buy” rating and set a $10.00 price target on shares of Viewray in a research note on Friday, November 17th. Finally, Mizuho reaffirmed a “buy” rating and set a $12.00 price target on shares of Viewray in a research note on Monday, November 13th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $10.60.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.